With 30% of COPD cases misdiagnosed, experts call for improved diagnostic strategies, better disease classification, and ...

Share on Pinterest GLP-1 and SGLT-2 drugs may be the best treatments ... to DPP-4i suggests these medications could be better options for patients with diabetes and COPD,” Patorno said.

The progressive nature of COPD, characterized by persistent ... will help refine our understanding of how these medications can best serve patients managing multiple chronic conditions ...

After a long road that included a three-month delay as the agency pushed for additional data, the US FDA has approved Sanofi and Regeneron's Dupixent (dupilumab) for COPD - as has China's National ...

General Manager at Sanofi UK and Ireland, Rippon Ubhi, and Jim Shannon MP discuss the burden of chronic obstructive pulmonary ...

The risk for moderate or severe COPD exacerbation was lower among those treated with SGLT-2is and with GLP-1 RAs versus DPP-4is.

Chronic obstructive pulmonary disease ... COPD is treatable. "The mainstays of therapy have historically been inhaled bronchodilators and inhaled steroids," says Han. Such medications can reduce ...

Chronic obstructive pulmonary disease (COPD) has seen no new therapies brought to market for around 10 years – and now there have been two in the space of a couple of weeks. The European ...

chronic obstructive pulmonary disease (COPD), and patients who have received a lung transplant. It ...

The prevalence of fatigue among patients with chronic obstructive pulmonary disease (COPD) worldwide is approximately 59%, according to systematic review and meta-analysis findings published in ...

reported in the New England Journal of Medicine that patients with COPD and type 2 inflammation who received the biologic agent dupilumab had fewer exacerbations, better lung function, and less severe ...